Chloroquine sulphate chronic discoid lupus erythematosus

Discussion in 'Hydroxychloroquine 200mg' started by Baltun, 12-Mar-2020.

  1. kiberNETik New Member

    Chloroquine sulphate chronic discoid lupus erythematosus


    -Suppressive therapy should continue for 8 weeks after leaving the endemic area. -Each dose should be taken with a meal or a glass of milk.

    Plaquenil cause hair loss reddit Plaquenil afecta los ojos Chloroquine hyposalinity Hydroxychloroquine medline plus

    PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis. PLAQUENIL is indicated for the treatment of acute and chronic rheumatoid arthritis in adults. CONTRAINDICATIONS. Use of PLAQUENIL is contraindicated in patients with known hypersensitivity to 4­ Hydroxychloroquine is the drug of choice when a systemic agent is needed for discoid lupus erythematosus DLE. Chloroquine is second-line antimalarial therapy. Chloroquine and hydroxychloroquine should not be used in combination due to the increased risk of ocular toxicity. PLAQUENIL is indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis PLAQUENIL is indicated for the treatment of acute and chronic rheumatoid arthritis in adults.

    -Concomitant therapy with an 8-aminoquinoline drug is necessary for the radical cure of vivax and malariae malaria. Use: Malaria prophylaxis Acute attack: 800 mg (620 mg base) orally followed in 6 to 8 hours by 400 mg (310 mg base), then 400 mg (310 mg base) once a day for 2 consecutive days; alternatively, a single dose of 800 mg (620 mg base) has also been effective Alternate dosing based on body weight: A total dose representing 25 mg/kg is administered in 3 days, as follows: First dose: 10 mg base/kg (not to exceed 620 mg base) orally Second dose: 5 mg base/kg (not to exceed 310 mg base) orally 6 hours after first dose Third dose: 5 mg base/kg orally 18 hours after second dose Fourth dose: 5 mg base/kg orally 24 hours after third dose Comments: -Each dose should be taken with a meal or a glass of milk.

    Chloroquine sulphate chronic discoid lupus erythematosus

    Discoid Lupus Erythematosus of the Eyelids, Discoid Lupus Erythematosus Medication Antimalarial.

  2. Hydroxychloroquine skin peeling
  3. Mechanism of action of chloroquine pdf
  4. Plaquenil genetic
  5. Plaquenil appetite
  6. Hydroxychloroquine and chloroquine retinopathy pdf
  7. Aug 30, 2017 Discoid lupus discoid lupus erythematosus is a chronic autoimmune disease affecting the skin. It gets its name from the coin-shaped lesions it produces. This condition causes a severe rash that tends to get worse when exposed to sunlight.

    • Discoid Lupus Rash Symptoms, Treatment, and Causes.
    • PLAQUENIL® HYDROXYCHLOROQUINE SULFATE TABLETS, USP.
    • Cutaneous Lupus Erythematosus Diagnosis and treatment.

    Sep 01, 2019 Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. Full text Full text is available as a scanned copy of the original print version. Get a printable copy PDF file of the complete article 384K, or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. However, this medicine is not used to treat severe or complicated malaria. Hydroxychloroquine is used to treat discoid lupus erythematosus DLE or systemic lupus erythematosus SLE or lupus. It is also used to treat acute and chronic rheumatoid arthritis.

     
  8. Slomn User

    Hydroxychloroquine (Plaquenil) is considered a disease-modifying anti-rheumatic drug (DMARD). Plaquenil Oral Uses, Side Effects, Interactions, Pictures, Warnings. How long does Hydroxychloroquine stay in your system? How Long Does It Take for Medicine to Absorb?
     
  9. IRINAK Moderator

    Dosing schedules not well established in children Case reports describe dosage regimens that are effective yet tolerated, such as 12.5 mg PO twice weekly over 2 yr in a child aged 4-6 yr, and 100 mg PO twice weekly over 5 months in a child aged 12 yr; mg/kg dosing not reported Hypersensitivity to chloroquine, 4-aminoquinolones Psoriasis, porphyria, retinal or visual field changes For prevention, may use proguanil concomitantly Shown to cause severe hypoglycemia including loss of consciousness that could be life-threatening in patients treated with or without antidiabetic medications; patients should be warned about risk of hypoglycemia and associated clinical signs and symptoms; patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with chloroquine should have blood glucose level checked and treatment reviewed as necessary Not effective in most areas; CDC recommends mefloquine or atovaquone/proguanil - check CDC traveler information for specific recommendations for region May cause hemolysis in glucose-6 phosphate dehydrogenase (G-6-PD) deficiency; blood monitoring may be needed as hemolytic anemia may occur, in particular in association with other drugs that cause hemolysis Monitor CBC periodically with prolonged therapy Caution with history of auditory damage Caution with hepatic disease, alcoholism, and coadministration with other hepatotoxic drugs May provoke seizures in patients with history of epilepsy Antacids and kaolin reduce chloroquine absorption; separate administration by at least 4 hr Irreversible retinal damage observed in some patients; significant risk factors for retinal damage include daily doses of chloroquine phosphate 2.3 mg/kg of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate, and concurrent macular disease A baseline ophthalmological examination should be performed within the first year of initiating therapy; for individuals with significant risk factors, monitoring should include annual examinations; discontinue if ocular toxicity is suspected; patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy In individuals of Asian descent, retinal toxicity may first be noticed outside macula; it is recommended that visual field testing be performed in visual field of central 24 degrees instead of central 10 degrees May exacerbate heart failure Not effective against chloroquine- or hydroxychloroquine-resistant strains of Plasmodium species; information regarding geographic areas where resistance to chloroquine occurs, is available at the Centers for Disease Control and Prevention (gov/malaria) Does not treat hypnozoite liver stage forms of Plasmodium and will therefore not prevent relapses of malaria due to P. ovale; additional treatment with an anti-malarial agent active against these forms, such as an 8-aminoquinoline, is required for the treatment of infections with P. ovale Cases of cardiomyopathy resulting in cardiac failure, in some cases with fatal outcome, reported during long term therapy at high doses; monitor for signs and symptoms of cardiomyopathy and discontinue chloroquine if cardiomyopathy develops; chronic toxicity should be considered when conduction disorders (bundle branch block / atrio-ventricular heart block) diagnosed; if cardiotoxicity suspected, prompt therapy discontinuation may prevent life-threatening complications QT interval prolongation, torsades de pointes, and ventricular arrhythmias reported; risk is greater if chloroquine is administered at high doses; fatal cases reported; use with caution in patients with cardiac disease, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia ( There are no adequate and well-controlled studies evaluating the safety and efficacy of chloroquine in pregnant women; usage during pregnancy should be avoided except in prophylaxis or treatment of malaria when benefit outweighs potential risk to fetus Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue drug, taking into account potential clinical benefit of drug to mother A: Generally acceptable. Individual plans may vary and formulary information changes. WHO Model Prescribing Information Drugs Used in Parasitic. CHLOROQUINE Drug BNF content published by NICE Chloroquine Oral Route Precautions - Mayo Clinic
     
  10. Nat9 Moderator

    New insights into autophagosome–lysosome fusion Lysosome fusion are least understood, although there have been several recent advances. In this Commentary, we will summarize the current knowledge regarding autophagosome–lysosome fusion, focusing on mammals, and discuss the remaining questions and future directions of the field.

    New insights into autophagosome–lysosome fusion Journal.